Novel Immunopharmacological Drugs for the Treatment of Allergic Diseases

Ekaterini Tiligada, Daria Gafarov, Maria Zaimi, Joana Vitte, Francesca Levi-Schaffer

Research output: Contribution to journalReview articlepeer-review


The exponential rise in the prevalence of allergic diseases since the mid-twentieth century has led to a genuine public health emergency and has also fostered major progress in research on the underlying mechanisms and potential treatments. The management of allergic diseases benefits from the biological revolution, with an array of novel immunomodulatory therapeutic and investigational tools targeting players of allergic inflammation at distinct pathophysiological steps. Prominent examples include therapeutic monoclonal antibodies against cytokines, alarmins, and their receptors, as well as small-molecule modifiers of signal transduction mainly mediated by Janus kinases and Bruton’s tyrosine kinases. However, the first-line therapeutic options have yet to switch from symptomatic to disease-modifying interventions. Here we present an overview of available drugs in the context of our current understanding of allergy pathophysiology, identify potential therapeutic targets, and conclude by providing a selection of candidate immunopharmacological molecules under investigation for potential future use in allergic diseases.

Original languageAmerican English
Pages (from-to)481-506
Number of pages26
JournalAnnual Review of Pharmacology and Toxicology
StatePublished - 23 Jan 2024

Bibliographical note

Publisher Copyright:
Copyright © 2024 by the author(s).


  • allergy
  • biologics
  • eosinophils
  • immunopharmacology
  • mast cells
  • small-molecule drugs


Dive into the research topics of 'Novel Immunopharmacological Drugs for the Treatment of Allergic Diseases'. Together they form a unique fingerprint.

Cite this